Search
Close this search box.

Moderna Partners with OpenAI to Revolutionize mRNA Medicine

Both our companies have shared values and are research-driven organizations pushing the boundaries of technology to drive transformation

Moderna, Inc. and OpenAI have announced a groundbreaking collaboration aimed at harnessing the transformative power of artificial intelligence (AI) in healthcare and business. This collaboration marks a significant step forward in leveraging AI technology to advance the development and delivery of mRNA medicines, paving the way for revolutionary advancements in healthcare.

A Visionary Collaboration for AI Innovation

Moderna, renowned for its digital-first approach and early adoption of machine learning, joins forces with OpenAI, a leader in AI research and development. With a shared vision of AI’s potential to reshape the future of healthcare, the collaboration is poised to drive innovation and accelerate the delivery of life-changing mRNA medicines.

Stéphane Bancel, CEO of Moderna: “Just as the introduction of the personal computer in the 1980s changed the way we work and live, AI is on a path to completely transform our everyday lives – and OpenAI is helping to lead the way. Both our companies have shared values and are research-driven organizations pushing the boundaries of technology to drive transformation.”

Sam Altman, CEO of OpenAI: “Moderna is leading the way by empowering all of its employees to use AI to tackle complex problems. We look forward to continuing to collaborate with Moderna to bring a new generation of medicines to patients in need.”

Integrating AI into Moderna’s Operations

The collaboration between Moderna and OpenAI began in early 2023 with the launch of mChat, Moderna’s instance of ChatGPT built on OpenAI’s API. Since then, the adoption of AI within Moderna has soared, with over 80% internal utilization of mChat. This success has catalyzed the deployment of ChatGPT Enterprise across Moderna’s business functions, enhancing productivity and enabling personalized support through AI assistants embedded within the company’s operations.

Driving Innovation with AI-Assisted Research and Development

Moderna has deployed over 750 AI models, known as GPTs (Generative Pre-trained Transformers), across the company. These GPTs serve as assistants to Moderna’s employees, augmenting their roles and driving automation and productivity. Notably, Moderna’s Dose ID GPT utilizes ChatGPT Enterprise’s Advanced Data Analytics feature to optimize vaccine dose selection, prioritizing safety and efficacy in late-stage clinical trials.

Advancing mRNA Medicine Through Collaboration

The collaboration between Moderna and OpenAI exemplifies a commitment to innovation and research-driven collaboration in healthcare. By leveraging AI technology, Moderna aims to accelerate its mission of delivering impactful mRNA medicines to patients worldwide, while OpenAI continues to push the boundaries of AI research and development.

About Moderna

Moderna is a pioneer in the field of mRNA medicine, revolutionizing the way medicines are made and administered. With a focus on mRNA technology, Moderna develops therapeutics and vaccines for a wide range of diseases, including infectious diseases, immuno-oncology, rare diseases, and autoimmune diseases. The company’s innovative approach and global team strive to deliver unprecedented impact in human health through mRNA medicines.

About OpenAI

OpenAI is a leading AI research organization dedicated to advancing the field of artificial intelligence for the benefit of humanity. With a focus on research-driven innovation, OpenAI collaborates with partners across various industries to develop cutting-edge AI technologies and solutions. Through its commitment to responsible AI development, OpenAI aims to unlock the full potential of artificial intelligence for the betterment of society.

The collaboration between Moderna and OpenAI represents a significant step forward in harnessing the power of AI to revolutionize healthcare and drive innovation in mRNA medicine. As the partnership continues to evolve, it promises to deliver groundbreaking advancements that have the potential to transform the future of medicine and improve the lives of patients worldwide.

Picture of Anshika Mathews
Anshika Mathews
Anshika is an Associate Research Analyst working for the AIM Leaders Council. She holds a keen interest in technology and related policy-making and its impact on society. She can be reached at anshika.mathews@aimresearch.co
Subscribe to our Latest Insights
By clicking the “Continue” button, you are agreeing to the AIM Media Terms of Use and Privacy Policy.
Recognitions & Lists
Discover, Apply, and Contribute on Noteworthy Awards and Surveys from AIM
AIM Leaders Council
An invitation-only forum of senior executives in the Data Science and AI industry.
Stay Current with our In-Depth Insights
MachineCon 2024
Meet 100 Most Influential AI Leaders in USA
Our Latest Reports on AI Industry
Supercharge your top goals and objectives to reach new heights of success!

Cutting Edge Analysis and Trends for USA's AI Industry

Subscribe to our Newsletter